FR3149773B1 - Nouvelles combinaisons synergiques a base de fenm - Google Patents

Nouvelles combinaisons synergiques a base de fenm

Info

Publication number
FR3149773B1
FR3149773B1 FR2306309A FR2306309A FR3149773B1 FR 3149773 B1 FR3149773 B1 FR 3149773B1 FR 2306309 A FR2306309 A FR 2306309A FR 2306309 A FR2306309 A FR 2306309A FR 3149773 B1 FR3149773 B1 FR 3149773B1
Authority
FR
France
Prior art keywords
disease
fenm
pick
composition
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2306309A
Other languages
English (en)
Other versions
FR3149773A1 (fr
Inventor
Gilles Rubinstenn
Tangui Maurice
Aline Freyssin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier, Ecole Pratique des Hautes Etudes SAS, Rest Therapeutics SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR2306309A priority Critical patent/FR3149773B1/fr
Publication of FR3149773A1 publication Critical patent/FR3149773A1/fr
Application granted granted Critical
Publication of FR3149773B1 publication Critical patent/FR3149773B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention se rapporte à une composition comprenant une combinaison synergique de la fluoroéthylnormémantine (FENM) et d’au moins un agoniste ou modulateur positif du récepteur sigma-1. Plus particulièrement, l’invention se rapporte à ladite composition pour son utilisation en tant que médicament, encore plus particulièrement pour son utilisation dans le traitement d’une pathologie sélectionnée parmi les maladies neurogénétiques d’origine métabolique telles que la ganliosidose à GM2, la maladie de Krabbe, la maladie de Fabry, la sialidose de type I, la maladie de Gaucher, la maladie de Niemann-Pick de type C, la maladie de Refsum, la xanthomatose cérébrotendineuse, l’adrénoleucodystrophie, ou encore les tauopathies, synucléinopathies, les amyloïdopathies, la maladie d’Alzheimer, la maladie de Parkinson, l’atrophie multisystématisée, la maladie de Huntington, l'atrophie corticale postérieure, la maladie de Pick, l’épilepsie, la démence vasculaire, la démence fronto-temporale, la démence à corps de Lewy, la sclérose latérale amyotrophique. Figure à publier avec l’abrégé : FIGURE 5
FR2306309A 2023-06-19 2023-06-19 Nouvelles combinaisons synergiques a base de fenm Active FR3149773B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2306309A FR3149773B1 (fr) 2023-06-19 2023-06-19 Nouvelles combinaisons synergiques a base de fenm

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2306309 2023-06-19
FR2306309A FR3149773B1 (fr) 2023-06-19 2023-06-19 Nouvelles combinaisons synergiques a base de fenm

Publications (2)

Publication Number Publication Date
FR3149773A1 FR3149773A1 (fr) 2024-12-20
FR3149773B1 true FR3149773B1 (fr) 2026-04-17

Family

ID=88290642

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2306309A Active FR3149773B1 (fr) 2023-06-19 2023-06-19 Nouvelles combinaisons synergiques a base de fenm

Country Status (1)

Country Link
FR (1) FR3149773B1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2586436A1 (fr) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Utilisation d'agents anti-connexine pour améliorer l'effet thérapeutique d'un inhibiteur de l'acétylcholinestérase
GR1008233B (el) 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
FR3006193B1 (fr) 2013-05-29 2015-06-19 Holis Technologies Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda)
EP3903767A1 (fr) 2016-02-11 2021-11-03 SigmaThera SAS Igmésine à utiliser dans le traitement de maladies neurodégénératives
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
EP3968977A4 (fr) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York Compositions et méthodes contre les troubles affectifs induits par le stress et leurs symptômes associés
FR3110393B1 (fr) 2020-05-20 2022-05-06 Grn Consulting Compose et composition pour induire une neuroprotection

Also Published As

Publication number Publication date
FR3149773A1 (fr) 2024-12-20

Similar Documents

Publication Publication Date Title
Naumann et al. Why, when, and how general practitioners restore endodontically treated teeth: a representative survey in Germany
Byrne et al. Preloads generated with repeated tightening in three types of screws used in dental implant assemblies
Iadecola Vascular and metabolic factors in Alzheimer’s disease and related dementias: introduction
MA34120B1 (fr) Composition pharmaceutique
DE60121922D1 (de) Verfahren und zusammenstellung für einen suplantataufbau
MA29872B1 (fr) Procede d'amelioration de la fonction cognitive
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
Kanzow et al. Contemporary teaching of restoration repair at dental schools in Germany–Close to universality and consistency
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
Shimizu et al. Interaction between β-amyloid protein and heparan sulfate proteoglycans from the cerebral capillary basement membrane in Alzheimer’s disease
FR3149773B1 (fr) Nouvelles combinaisons synergiques a base de fenm
Habib et al. Concepts of restoring endodontically treated teeth among dentists in Saudi Arabia
Forlanini An attempt at reconstructing the branches of the Hittite royal family of the Early Kingdom period
Assunçao et al. Effect of misfit on preload maintenance of retention screws of implant-supported prostheses
FR3128872B1 (fr) Nouvelles combinaisons synergiques a base de fenm
Marnetoft et al. Vocational rehabilitation
Snyder Mesial margin ridging of incisor labial surfaces
CA2475116A1 (fr) Polypeptides impliques dans l'expression de la resistance aux antibiotiques glycopeptidiques
Barat et al. Heparin and the solubilization of asymmetric acetylcholinesterase
Lacambre et al. Pithana, an Anatolian ruler in the time of Samsuiluna of Babylon: New data from Tell Rimah (Iraq)
Goebel et al. 121st ENMC international workshop on desmin and protein aggregate myopathies. 7–9 November 2003, Naarden, The Netherlands
Sciulli et al. Phenotypic selection on the dentition in a Late Archaic population of Ohio
Davari et al. Effect of different synthetic matrix metalloproteinase inhibitors on composite-dentin microtensile bond strength durability
Pickerill Stomatology in general practice
Aparna et al. Tooth-implant connection: A critical review

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20241220

PLFP Fee payment

Year of fee payment: 3